Results 91 to 100 of about 39,316 (219)

Oncogenic KRAS Rewires Stress Granule Dynamics: Mechanisms and Therapeutic Opportunities

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Stress granules (SGs) are dynamic, membrane‐less structures that form in response to various cellular stresses, including metabolic, oxidative, and therapeutic challenges. They function as adaptive hubs and reorganize protein synthesis and signaling networks to help cells survive under stress. In cancer, these condensates are often hijacked to
Msimisi Ndzinisa, Birhanetensay Masresha Altaye, Yuh‐Pyng Sher   +2 more
wiley   +1 more source

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Haematologica, 2012
Background Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment.
Silvia C. W. Ling, Edwin K. K. Lau, Ammira Al-Shabeeb, Angela Nikolic, Albert Catalano, Harry Iland, Noemi Horvath, P. Joy Ho, Simon Harrison, Shaun Fleming, Douglas E. Joshua, John D. Allen   +11 more
doaj   +1 more source

Protein phosphatase 5 modulates SMAD3 function in the transforming growth factor-beta pathway [PDF]

, 2012
Protein phosphatases play a key role in balancing the cellular responses to the transforming growth factor-beta (TGF beta) signals. Several protein phosphatases have been attributed roles in the regulation of the TGF beta pathway. Among these.
Bruce, David L., Macartney, Thomas, Sapkota, Gopal P., Shou, Weinian, Yong, Weidong   +4 more
core   +3 more sources

Aliphatic Poly(Carbonate)s with Acid Responsive Release Mechanisms for Micellar Anti‐Tumor Drug Delivery

Macromolecular Rapid Communications, EarlyView.
Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley   +1 more source

Reduction of SIRT1 epigenetically upregulates NALP1 expression and contributes to neuropathic pain induced by chemotherapeutic drug bortezomib

Journal of Neuroinflammation, 2018
Background Bortezomib is a frequently used chemotherapeutic drug for the treatment of multiple myeloma and other nonsolid malignancies. Accumulating evidence has demonstrated that bortezomib-induced persistent pain serves as the most frequent reason for ...
Kun Chen, Jing Fan, Zhao-Fan Luo, Ying Yang, Wen-Jun Xin, Cui-Cui Liu   +5 more
doaj   +1 more source

Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury. a Case Series [PDF]

, 2018
Background/Aims: Multiple myeloma (MM) represents 10% of all haematologic malignancies. Renal involvement occurs in 50% of MM patients; of them, 12-20% have acute kidney injury (AKI), with 10% needing dialysis at presentation. While hemodialysis (HD) has
Antolino, Giusy, Festuccia, Francescaromana, Fofi, Claudia, Giammarioli, Elisa, La Verde, Giacinto, Mene, Paolo, Punzo, Giorgio, Tafuri, Agostino   +7 more
core   +2 more sources

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, EarlyView.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

A Case Report of a Special Type of Multiple Myeloma: Kappa Light Chain‐Only

Organ Medicine, EarlyView.
This case illustrates the clinical course of a patient diagnosed with kappa light chain‐only multiple myeloma, a rare subtype of multiple myeloma. Of note, light chain multiple myeloma is characterized by rapid disease progression and severe target organ damage.
Yanhua Dai, Yuanyue Guan, Shiwei Cui, Yuan Gao, Zhipeng Zhao, Rui Li, Li Song, Xiuying Zhao, Runqing Li   +8 more
wiley   +1 more source

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma

Frontiers in Oncology, 2019
Multiple myeloma (MM) drug resistance highlights a need for alternative therapeutic strategies. In this study, we show that CASIN, a selective inhibitor of cell division cycle 42 (Cdc42) GTPase, inhibited proliferation and survival of melphalan ...
Phuong Nguyen, Phuong Nguyen, Jayati Chakrabarti, Jayati Chakrabarti, Yuan Li, Yuan Li, Khalid W. Kalim, Khalid W. Kalim, Mengnan Zhang, Lin Zhang, Yi Zheng, Yi Zheng, Fukun Guo, Fukun Guo   +13 more
doaj   +1 more source